Journal
ANTIVIRAL RESEARCH
Volume 160, Issue -, Pages 118-125Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.antiviral.2018.10.019
Keywords
Zika virus; NS2B/NS3 proteinase; Suramin; Inhibitor; Lead compound
Categories
Funding
- CNPq [435913/2016-6, 401270/2014-9, 307338/2014-2]
- FAPESP [2015/13765-0, 2015/18868-2, 2016/08104-8, 2016/12904-0, 2009/53989-4]
- CAPES
- PROPe UNESP
Ask authors/readers for more resources
Zika virus infection is the focus of much research due to the medical and social repercussions. Due the role of the viral NS2B/NS3 proteinase in maturation of the viral proteins, it had become an attractive antiviral target. Numerous investigations on viral epidemiology, structure and function analysis, vaccines, and therapeutic drugs have been conducted around the world. At present, no approved vaccine or even drugs have been reported. Thus, there is an urgent need to develop therapeutic agents to cure this epidemic disease. In the present study, we identified the polyanion suramin, an approved antiparasitic drug with antiviral properties, as a potential inhibitor of Zika virus complex NS2B/NS3 proteinase with IC50 of 47 mu M. Using fluorescence spectroscopy results we could determine a k(d) value of 28 mu M and had shown that the ligand does not affect the thermal stability of the protein. STD NMR spectroscopy experiments and molecular docking followed by molecular dynamics simulation identified the binding epitopes of the molecule and shows the mode of interaction, respectively. The computational analysis showed that suramin block the Ser135 residue and interact with the catalytically histidine residue.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available